DEWB AG Deutsche Effecten- und Wechsel-Beteiligungsgesellschaft AG

DEWB Investment Holding NOXXON Presents Data from Phase IIa Study with NOX-H94 - Seite 2

About NOXXON Pharma AG NOXXON Pharma is a biopharmaceutical company pioneering the development of a new class of proprietary therapeutics called Spiegelmers. Spiegelmers are chemically synthesized L-stereoisomer oligonucleotide aptamers, a non-immunogenic alternative to antibodies. NOXXON has a diversified portfolio of clinical-stage Spiegelmer® therapeutics:

- Emapticap pegol (NOX-E36), an anti-CCL2/MCP-1 (C-C chemokine ligand 2 / Monocyte Chemoattractant Protein-1) Spiegelmer®, has successfully completed a Phase IIa study in patients with type 2 diabetes with albuminuria, achieving proof-of-concept. CCL2 is a pro-inflammatory chemokine involved in the recruitment of immune cells to inflamed tissues. - Olaptesed pegol (NOX-A12), an anti-CXCL12/SDF-1 (CXC chemokine ligand 12 / Stromal Cell-Derived Factor-1) Spiegelmer®, is currently in Phase IIa studies in two hematological cancers, multiple myeloma (MM) and chronic lymphocytic leukemia (CLL). CXCL12 is a chemokine mediator of tumor invasion, metastasis, and resistance to therapy. - Lexaptepid pegol (NOX-H94), an anti-hepcidin Spiegelmer®, has completed a Phase IIa pilot study in cancer patients with anemia and will soon begin a study in EPO-hyporesponsive dialysis patients. Hepcidin is the key regulator of iron metabolism and responsible for the iron restriction leading to anemia of chronic disease.

The Spiegelmer® platform provides the company with powerful and unique discovery capabilities, which have generated a number of additional leads under preclinical investigation. Located in Berlin, Germany, NOXXON is a well-financed mature biotech company with a strong syndicate of interna¬tional investors, and approximately 60 employees.

For more information, please visit: www.noxxon.com

Contact:

NOXXON Pharma AG Emmanuelle Delabre T: [phone] [e-mail]

Instinctif Partners Robert Mayer / Cora Kaiser T: [phone] [e-mail]

(1) Ludwig H, et al. European Journal of Cancer, Vol. 45(9), 1603-1615, 2009.



(end)

emitter: DEWB AG Deutsche Effecten- und Wechsel-Beteiligungsgesellschaft AG address: Fraunhoferstraße 1, 07743 Jena country: Germany contact person: Marco Scheidler phone: [phone] e-mail: [e-mail] website: www.dewb.de

ISIN(s): DE0008041005 (share) stock exchanges: entry standard in Frankfurt, free market in Stuttgart, free market in Munich, free market in Hamburg, free market in Dusseldorf, free market in Hannover; open market in Berlin

[ source: http://www.pressetext.com/news/20140408031 ]